Safety and durable immunogenicity of the TV005 tetravalent dengue vaccine, across serotypes and age groups, in dengue-endemic Bangladesh: a randomised, controlled trial-Reference-Cited by-同舟云学术

Safety and durable immunogenicity of the TV005 tetravalent dengue vaccine, across serotypes and age groups, in dengue-endemic Bangladesh: a randomised, controlled trial

Published:2024-02 Issue:2 Volume:24 Page:150-160
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Walsh Mary-Claire R,Alam Mohammed Shafiul,Pierce Kristen K,Carmolli Marya,Alam Masud,Dickson Dorothy M,Bak Dan M,Afreen Sajia,Nazib Forida,Golam Kibria,Qadri Firdausi,Diehl Sean A,Durbin Anna P,Whitehead Stephen S,Haque Rashidul,Kirkpatrick Beth D

Funder

Johns Hopkins University

Johns Hopkins University Bloomberg School of Public Health

National Institutes of Health

Division of Intramural Research, National Institute of Allergy and Infectious Diseases

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference29 articles.

1. The global distribution and burden of dengue;Bhatt;Nature,2013

2. Dengue infection;Guzman;Nat Rev Dis Primers,2016